Current opportunities:

The following compounds are currently open for out licensing and/or co-development with a strategic partner:

HSV Pritelivir (AIC316)

Pritelivir - The perfect solution for resistant HSV infections at immunocompromised patients.

AIC649

AIC649 - Proprietary Immune Modulator and Potential Cure for Chronic Hepatitis B Infection

 
 
Dr. Igor Orshanskiy
Associate Director
Business Development &
Alliance Management
 
AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal
 
Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: business@aicuris.com